Efficacy of androgen deprivation therapy and the role of oxidative stress

被引：6
作者：
Price, D. K. [1 ]
机构：
[1] Natl Canc Inst, Natl Inst Hlth, Genitourinary Malignancies Branch, Bethesda, MD USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷 / 03期
基金：
美国国家卫生研究院;
关键词：
RESISTANT PROSTATE-CANCER; INCREASED SURVIVAL; MITOXANTRONE; PREDNISONE;
D O I：
10.1093/annonc/mdx001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：451 / 453
页数：4
相关论文
共 50 条
  • [41] Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
    Rajan, Prabhakar
    Sudbery, Ian M.
    Villasevil, M. Eugenia M.
    Mui, Ernest
    Fleming, Janis
    Davis, Mark
    Ahmad, Imran
    Edwards, Joanne
    Sansom, Owen J.
    Sims, David
    Ponting, Chris P.
    Heger, Andreas
    McMenemin, Rhona M.
    Pedley, Ian D.
    Leung, Hing Y.
    EUROPEAN UROLOGY, 2014, 66 (01) : 32 - 39
  • [42] Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer
    Saad, Fred
    Fizazi, Karim
    UROLOGY, 2015, 86 (05) : 852 - 861
  • [43] Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
    Roy, Soumyajit
    Sayyid, Rashid
    Saad, Fred
    Sun, Yilun
    Lajkosz, Katherine
    Ong, Michael
    Klaassen, Zachary
    Malone, Shawn
    Spratt, Daniel E.
    Wallis, Christopher J. D.
    Morgan, Scott C.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 494 - 502
  • [44] Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor
    Lazaro Quintela, Martin
    Leon Mateos, Luis
    Vazquez Estevez, Sergio
    Fernandez Calvo, Ovidio
    Anido Herranz, Urbano
    Afonso Afonso, Francisco Javier
    Santome, Lucia
    Anton Aparicio, Luis
    CANCER TREATMENT REVIEWS, 2015, 41 (03) : 247 - 253
  • [45] Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway
    Ardiani, Andressa
    Gameiro, Sofia R.
    Kwilas, Anna R.
    Donahue, Renee N.
    Hodge, James W.
    ONCOTARGET, 2014, 5 (19) : 9335 - 9348
  • [46] Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy
    Hamid, Agus Rizal A. H.
    Kusuma Putra, Harun W.
    Sari, Ningrum Paramita
    Diana, Putri
    Sesari, Saras Serani
    Novita, Eka
    Gultom, Fajar Lamhot
    Saraswati, Meilania
    Tanurahardja, Budiana
    Asmarinah
    Umbas, Rainy
    Mochtar, Chaidir A.
    BMC UROLOGY, 2020, 20 (01)
  • [47] Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
    Marshall, Catherine H.
    Tunacao, Jessa
    Danda, Varun
    Tsai, Hua-Ling
    Barber, John
    Gawande, Rakhee
    Weiss, Clifford R.
    Denmeade, Samuel R.
    Joshu, Corinne
    BJU INTERNATIONAL, 2021, 128 (03) : 366 - 373
  • [48] Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review
    Liang, Zhen
    Zhu, Jun
    Chen, Longlong
    Xu, Yawei
    Yang, Yongjiao
    Hu, Rui
    Zhang, Wei
    Song, Yuxuan
    Lu, Yi
    Ou, Ningjing
    Liu, Xiaoqiang
    ANDROLOGY, 2020, 8 (03) : 559 - 574
  • [49] The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer
    Patel, S. A.
    Chen, M-H
    Loffredo, M.
    Renshaw, A.
    Kantoff, P. W.
    D'Amico, A. V.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (02) : 234 - 240
  • [50] Quality of life in patients diagnosed of prostate cancer treated with continuous androgen deprivation therapy vs. intermittent therapy. Prospective study through the application of the CAVIPRES questionnaire
    Sierra Labarta, C. R.
    Sanchez Zalabardo, D.
    de Pablo Cardenas, A.
    ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2015, 38 (02) : 193 - 201
12345